longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

COHN

COHN
----

LongbridgeAI

Cohen & Co Inc. 2Q 2026: Revenue $69.5M, EPS $0.94— 10-Q Summary

TradingView
Aug 3, 2026 at 02:31 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Cohen & Co Inc. reported Q2 2026 revenue of $69.5M, up 16% YoY, and diluted EPS of $0.94, up 16%. Net income surged 154% to $3.57M. Growth was driven by a 55% rise in investment banking revenue, improved net trading activity, and stable asset-management fees. Key highlights include significant advisory shifts toward CCM and notable SPAC sponsorship activities.

Cohen & Co Inc. reported second-quarter 2026 results with revenue of $69.5M and diluted EPS of $0.94, driven by strength in investment banking, trading and mortgage operations and continued asset-management fee stability versus the prior-year quarter.

Financial Highlights

  • Revenue was $69.5M for 2Q 2026, up from $59.9M in 2Q 2025; YoY change 16%.
  • Net income attributable to Cohen & Company Inc. was $3.57M for 2Q 2026, versus $1.41M in 2Q 2025; YoY change 154%.
  • Diluted earnings per share was $0.94 for 2Q 2026, compared with $0.81 in 2Q 2025; YoY change 16%.

Business Highlights

  • Revenue growth was led by investment banking and new-issue revenue, which rose 55% year-to-date and helped lift total revenues 44% YTD.
  • Advisory and underwriting activity shifted materially toward CCM, including deals with non-cash consideration that boosted the firm's fee mix.
  • Net trading activity improved 36% YTD, supported by gestation repo, CMOs and SPAC-related equity positions.
  • Asset-management momentum continued with diversified AUM across Pride funds, a U.S. insurance joint venture and CREO JV; management fees remained stable despite some AUM fluctuations.
  • SPAC sponsorships and principal-investment activity were notable, including a completed Columbus Circle I de-SPAC and an announced Columbus Circle II transaction.

Original SEC Filing: Cohen & Co Inc. [ COHN ] - 10-Q - Aug. 03, 2026

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Login to unlock1,085characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Cohen

Cohen

USCOHN

+0.37%

Concord Medical

Concord Medical

USCCM

-2.27%